Preparation of Argatroban Analog Thrombin Inhibitors with Reduced Basic Guanidine Moiety, and Studies of Their Cell Permeability and Antithrombotic Activities

Medicinal Chemistry Research

Volumn 6, Issue 6, 1996, Pages 377-383

  Kim, Kyoung Soon ^a   Moquin, Robert V ^a   Qian, Ligang ^a   Morrison, Richard A ^a   Seiler, Steven M ^a   Roberts, Daniel G M ^a   Ogletree, Martin L ^a   Youssef, Sonia ^a   Chong, Saeho ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000616292     PISSN: 10542523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. (a) Fenton, J. W., II Ann. N. Y. Acad. Sci., 1986, 485, 5.
2. (b) Fenton. J. W., II; Ofosu, F. A.; Moon, D. G.; Maraganore, J. M. Blood Coagulation and Fibrinolysis 1991, 2, 69.
3. Banner, D.; Ackermann, J.; Gast, A.; Gubernator, K.; Hadvary, P.; Hilpert, K.; Labler, L.; Muller, K.; Schmid, G.; Tschopp, T.; Waterbeemd, H.; Wirz, B. In Perspectives in Medicinal Chemistry; chaptrer 3, Testa, B.; Kyburz, E.; Fuhrer, W.; Giger, R. Ed.; Verlag Helvetica Chimica Acta, Basel, 1993.
4. Kikumoto, R.; Tamao, Y.; Ohkubo, K.; Tezuka, T.; Tonomura, S.; Okamoto, S.; Hijikata, A. J. Med. Chem. 1980, 23, 1293.
5. Bajusz, S.; Barabas, E.; Tolnay, P.; Szell, E.; Badgy, D. Int. J. Peptide Protein Res. 1978, 12, 217.
6. Stubbs, M. T.; Bode, W. Thrombosis Res. 1993, 69, 1.
7. (a) Sturzebecher, J.; Wikstroem, P. Patent Appl. WO 92/16549, Oct.1, 1992.
8. (b) Onshima, O.; Iwase, N.; Sugiyama, S. European Patent Appl. 669317A1, Aug. 30, 1995.
9. pKa of L-canavanine : 2.35, 7.01, 9.22 Boyar, A.; Marsh, R. E. J. Am. Chem. Soc., 1982, 104, 1995. Tomiyama, T. J. Biol. Chem.,1935, 111, 45-49. pKa of L-arginine : 2.18, 9.09, 13.2 The Merck Index; 10th ed.; Windholz, M. Ed.; Merck & Co., Inc., 1983; p797.
10. pKa of L-canavanine : 2.35, 7.01, 9.22 Boyar, A.; Marsh, R. E. J. Am. Chem. Soc., 1982, 104, 1995. Tomiyama, T. J. Biol. Chem.,1935, 111, 45-49. pKa of L-arginine : 2.18, 9.09, 13.2 The Merck Index; 10th ed.; Windholz, M. Ed.; Merck & Co., Inc., 1983; p797.
11. pKa of L-canavanine : 2.35, 7.01, 9.22 Boyar, A.; Marsh, R. E. J. Am. Chem. Soc., 1982, 104, 1995. Tomiyama, T. J. Biol. Chem.,1935, 111, 45-49. pKa of L-arginine : 2.18, 9.09, 13.2 The Merck Index; 10th ed.; Windholz, M. Ed.; Merck & Co., Inc., 1983; p797.
12. (a) pKa of 4,4-Difluoro-L-arginine : 1.4, 8.1, 11.2 , Kim, K. S.; Qian, L. Tetrhedron Lett.. 1993, 34, 7195.
13. (b) pKa of compound 4 : 8.50, 9.15, 10.76 (for sulfonamide proton).
14. Shimizu, Y.; Hsu, C.; Fallon, W.E.; Oshima, Y. J. Am. Chem. Soc. 1978, 100, 6791.
15. Mitsunobu, O. Synthesis 1981, 1.
16. (a) Okamoto, S.; Hijikata, A.; Kikumoto, R.; Tamao, Y.; Ohkubo, K.; Tezuka, T.; Tonomura, S. US Patent 4, 117, 127. 1978.
17. (b) Okamoto, S.; Hijikata, A.; Kikumoto, R.; Tamao, Y.; Ohkubo, K.; Tezuka, T.; Tonomura, S. US Patent 4, 258, 192. 1981.
18. (a) Poss, M. A.; Iwanowicz, E.; Reid, J. A.; Lin, J.; Gu, Z. Tetrahedron Lett. 1992, 33, 5933.
19. (b) Kim, K. S.; Qian, L. Tetrahedron Lett. 1993, 34, 7677.
20. (a) Garner, P.; Park, J. M. J. Org. Chem. 1987, 52, 2361.
21. (a) Miller, A. E.; Bischoff, J. J. Synthesis 1986, 777.
22. (b) Bernatowicz, M. S.; Wu, Y.; Matsueda, G. R. J. Org. Chem. 1992, 57, 2497.
23. Itzstein, V.; Wu, W.; Phan, T. V.; Jin, B. European Patent 0539204 A1, 1992.
24. (a) Artursson, P.; Karlsson, J. Biochem. Biophy. Res. Comm. 1991, 175, 880.
25. (b) Hidalgo, I. J. ; Raub, T. J.; Borchardt, R. T. Gastroenterology 1989, 96, 736.
26. Meacham, R.H.; Emmett, M.; Kyriakopoulos, A.A.; Chiang, S.T.; Ruelius, H.W.; Walker, B.R.; Narins, R.G.; Goldberg, M. Clin. Pharmacol. Ther. 1980, 27, 44.
27. 50 determinations). The enzymatic reaction was started with 10 μL of 3 mM S-2238 substrate and continued at room temperature. The change in optical density was measured at 405 nm. A kinetic microplate reader (Molecular Devices Corporation Vmax) was used to measure the change in optical density over time.
28. 2 asphyxiation. Survival of >20% in any group was considered significant, and the dose by a particular route producing 50% survival was calculated by log-linear interpolation.
29. (a) Banner, D. W.; Hadvary, P. J. Biol. Chem. 1991, 266, 20085.
30. (b) Brandstetter, H.; Turk, D.; Hoeffken, H. W.; Grosse, D.; Sturzebecher, J.; Martin, P. D.; Edwards, B. F. P.; Bode, W. J. Mol. Biol. 1992, 226, 1085.
31. N-Hydroxyguanidine in Neosaxitoxin being easily biotransformed to guanidine in shell fish (Shimizu, Y; Yoshioka, Y. Science, 1981, 212,547) it deserves further metabolic studies in human as a potential prodrug of arginine containing molecules.